Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2005

View Archived Issues

Paradigm Therapeutics and Takeda sign CNS alliance

Baxter to support Morphotek's therapeutic antibody pipeline

Investigators seek extension to phase IIb study of HCV therapeutic E1 vaccine

New agents for heart failure, atherosclerosis and other cardiovascular diseases reported

M-40403 alleviates periodontitis in rats

New antidiabetic agents in early development

FDA accepts Epix' Vasovist submission as complete response

Chronogen and Inpharzam Ricerche to screen innovative drug candidates

Medtronic acquires Transneuronix

Acrux receives license fee from Vivus for Evamist

Lipoxygenase inhibitor decreases proteinuria, preserves renal function in diabetic nephropathy

LAS-34273 demonstrates fast and sustained 24-hour bronchodilator effect

Pharmasset licenses clevudine for HBV from Bukwang

Osteoprotegerin blocks lytic cancer lesions in bones

A.C.T. Holdings changes name to Advanced Cell Technology

Pfizer provides update on two drug candidates

Prodrugs of GluR5 antagonists effective in several animal models of pain

Retisert launched for chronic noninfectious uveitis

U.S. launch for Aptivus

Depo-Provera reported to induce changes in bone mineral density of women

Novartis inlicenses A-60444 for RSV

New data on the efficacy of DX-88 in hereditary angioedema

Antitumor effects reported for CGC-11047 in lymphoma

Exubera inhaled insulin reported safe and effective in diabetes

Tesaglitazar improves lipid and glucose parameters of diabetic and insulin-resistant patients

Armodafinil improves daytime wakefulness in OSA/HS patients